6-methylthiopurine has been researched along with Bowel Diseases, Inflammatory in 46 studies
6-methylthiopurine : A thiopurine that is 9H-purine substituted by a methylsulfanyl group at position 6.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We aimed to describe our center's experience with thiopurine optimization through the use of reduced thiopurine dosing in combination with allopurinol upon hepatotoxicity, drug metabolite levels, and clinical outcomes in children with IBD." | 5.48 | Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases. ( Boyle, B; Bricker, J; Crandall, W; Dotson, JL; Kim, SC; Maltz, R; Serpico, MR, 2018) |
| "Recent studies in patients with inflammatory bowel diseases (IBD) on thiopurine therapy suggest that too low 6-thioguanine nucleotide concentrations (6-TGN) and too high methylmercaptopurine nucleotide concentrations (MMPN) can be reversed by a combination therapy of allopurinol and low-dose thiopurines." | 5.17 | Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations. ( Curkovic, I; Frei, P; Fried, M; Jetter, A; Kullak-Ublick, GA; Rentsch, KM; Rogler, G, 2013) |
| " Participants with optimal dosing in the morning had an earlier chronotype by corrected midpoint of sleep." | 3.30 | Impact of Chronotherapy on 6-Mercaptopurine Metabolites in Inflammatory Bowel Disease: A Pilot Crossover Trial. ( Biglin, M; Bishehsari, F; Chouhan, V; Francey, L; Hogenesch, J; Jochum, S; Keshavarzian, A; Raff, H; Shaikh, M; Swanson, GR, 2023) |
| "Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adverse reactions of azathioprine and mercaptopurine in IBD patients, often related to high steady-state 6-methylmercaptopurine ribonucleotide (6-MMPR) metabolite concentrations." | 2.84 | Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease. ( Coenen, MJ; de Jong, DJ; Derijks, LJ; Engels, LG; Franke, B; Guchelaar, HJ; Hooymans, PM; Klungel, OH; Scheffer, H; van Marrewijk, CJ; Verbeek, AL; Vermeulen, SH; Wong, DR, 2017) |
| "Pregnancy has a major effect on maternal thiopurine metabolism." | 2.79 | Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. ( de Boer, NK; de Jong, DJ; Dijkstra, G; Hommes, DW; Jharap, B; Mulder, CJ; Oldenburg, B; Stokkers, P; van Bodegraven, AA; van der Woude, CJ; van Elburg, RM, 2014) |
| " However, adverse events leading to discontinuation may occur in 10-20% of patients." | 2.71 | 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment. ( de Jong, DJ; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Jansen, JB; Mulder, CJ, 2003) |
| " However, because of their complex metabolism and potential toxicities, optimal use of biomarkers to predict adverse effects and therapeutic response is paramount." | 2.53 | Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. ( Loftus, EV; Moon, W, 2016) |
| " For patients with severe ulcerative colitis (UC), steroid dosing has been clarified, and a mega-analysis of steroid outcomes and toxicities has been reported." | 2.44 | Optimizing drug therapy in inflammatory bowel disease. ( Kornbluth, A; Swaminath, A, 2007) |
| "Our primary aim was to assess infection rate and our secondary aims were to assess adverse reactions to vaccinations, growth, autoimmune diseases and malignancies." | 1.62 | Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life. ( Beukers, R; Bodelier, A; de Boer, N; de Lima, A; Depla, ACTM; Dijkstra, G; Erler, N; Escher, JC; Gilissen, L; Hoentjen, F; Jansen, JM; Kanis, SL; Kuyvenhoven, J; Mahmmod, N; Mallant-Hent, RC; Modderman, S; Noruzi, A; Oldenburg, B; Oostenbrug, LE; Pierik, M; Romberg-Camps, M; Ter Borg, PCJ; Thijs, W; van der Meulen-de Jong, AE; van der Woude, CJ; van Dijk, ARM; West, R, 2021) |
| " To assess if IFX influenced thiopurine metabolites, eight patients who had responded to 12 weeks of intensified IFX at a constant thiopurine dosing were included." | 1.48 | A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease. ( Ainsworth, MA; Brynskov, J; Mogensen, DV; Nersting, J; Schmiegelow, K; Steenholdt, C, 2018) |
| " Dosing history, concomitant therapy, and comorbidity data were assessed." | 1.48 | Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine. ( Barclay, ML; Mulder, CJ; Munnig-Schmidt, E; Zhang, M, 2018) |
| " We aimed to describe our center's experience with thiopurine optimization through the use of reduced thiopurine dosing in combination with allopurinol upon hepatotoxicity, drug metabolite levels, and clinical outcomes in children with IBD." | 1.48 | Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases. ( Boyle, B; Bricker, J; Crandall, W; Dotson, JL; Kim, SC; Maltz, R; Serpico, MR, 2018) |
| "Azathioprine dose was titrated on therapeutic efficacy (response and adverse effects)." | 1.46 | Multicentric Case-Control Study on Azathioprine Dose and Pharmacokinetics in Early-onset Pediatric Inflammatory Bowel Disease. ( Aloi, M; Arrigo, S; Barabino, A; Cuzzoni, E; Decorti, G; Favretto, D; Franca, R; Knafelz, D; Martelossi, S; Martinelli, M; Miele, E; Naviglio, S; Romano, C; Stocco, G; Ventura, A, 2017) |
| "This study explored the relationship between the weight-based dosage of AZA and metabolites levels in 86 pediatric IBD patients using multilevel analysis." | 1.39 | Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis. ( Boulieu, R; Lachaux, A; Nguyen, TM; Nguyen, TV; Vu, DH, 2013) |
| " Prospective studies are needed to determine whether routine testing to guide dosing is of benefit." | 1.39 | Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease. ( Andrews, JM; Asser, TL; Bampton, PA; Doogue, MP; Kennedy, NA; Mountifield, RE, 2013) |
| " The primary outcome was the occurrence of 6-thioguanine induced hepatotoxicity, scaled according to the Common Terminology Criteria for Adverse Events." | 1.38 | Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment. ( de Boer, NK; Mulder, CJ; Seinen, ML; van Asseldonk, DP; van Bodegraven, AA, 2012) |
| " Measuring thiopurine metabolites is useful for dosage adjustment in children, and for the detection of potential toxicity." | 1.37 | Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine. ( Armstrong, L; Bishop, J; Galloway, P; McGrogan, P; Russell, RK; Sharif, JA, 2011) |
| "Azathioprine treatment is a long-term therapy and therefore it is at risk for non-adherence, which is considered an important determinant of treatment inefficacy." | 1.36 | Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence. ( Bartoli, F; Campanozzi, A; Decorti, G; Londero, M; Malusa, N; Marino, S; Martelossi, S; Stocco, G; Ventura, A, 2010) |
| "Azathioprine (AZA) has a slow onset of action in treatment of pediatric inflammatory bowel disease (IBD)." | 1.36 | Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease. ( Beránek, M; Chládek, J; Dědek, P; Hroch, M; Krásničanová, P; Malý, J; Pozler, O, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (30.43) | 29.6817 |
| 2010's | 30 (65.22) | 24.3611 |
| 2020's | 2 (4.35) | 2.80 |
| Authors | Studies |
|---|---|
| Swanson, GR | 1 |
| Biglin, M | 1 |
| Raff, H | 1 |
| Chouhan, V | 1 |
| Jochum, S | 1 |
| Shaikh, M | 1 |
| Francey, L | 1 |
| Bishehsari, F | 1 |
| Hogenesch, J | 1 |
| Keshavarzian, A | 1 |
| Kanis, SL | 1 |
| Modderman, S | 1 |
| Escher, JC | 1 |
| Erler, N | 1 |
| Beukers, R | 1 |
| de Boer, N | 1 |
| Bodelier, A | 1 |
| Depla, ACTM | 1 |
| Dijkstra, G | 2 |
| van Dijk, ARM | 1 |
| Gilissen, L | 1 |
| Hoentjen, F | 1 |
| Jansen, JM | 1 |
| Kuyvenhoven, J | 1 |
| Mahmmod, N | 1 |
| Mallant-Hent, RC | 1 |
| van der Meulen-de Jong, AE | 1 |
| Noruzi, A | 1 |
| Oldenburg, B | 2 |
| Oostenbrug, LE | 1 |
| Ter Borg, PCJ | 1 |
| Pierik, M | 1 |
| Romberg-Camps, M | 1 |
| Thijs, W | 1 |
| West, R | 1 |
| de Lima, A | 1 |
| van der Woude, CJ | 2 |
| Waljee, AK | 2 |
| Sauder, K | 1 |
| Patel, A | 1 |
| Segar, S | 1 |
| Liu, B | 1 |
| Zhang, Y | 1 |
| Zhu, J | 2 |
| Stidham, RW | 1 |
| Balis, U | 1 |
| Higgins, PDR | 1 |
| Mogensen, DV | 1 |
| Brynskov, J | 1 |
| Ainsworth, MA | 1 |
| Nersting, J | 1 |
| Schmiegelow, K | 2 |
| Steenholdt, C | 1 |
| Wall, GC | 1 |
| Muktar, H | 1 |
| Effken, C | 1 |
| Mahajan, PB | 1 |
| Munnig-Schmidt, E | 1 |
| Zhang, M | 2 |
| Mulder, CJ | 6 |
| Barclay, ML | 5 |
| Serpico, MR | 1 |
| Maltz, R | 1 |
| Crandall, W | 1 |
| Bricker, J | 1 |
| Dotson, JL | 1 |
| Kim, SC | 1 |
| Boyle, B | 1 |
| Roberts, RL | 1 |
| Wallace, MC | 1 |
| Seinen, ML | 3 |
| van Bodegraven, AA | 6 |
| Krishnaprasad, K | 1 |
| Jones, GT | 1 |
| van Rij, AM | 1 |
| Baird, A | 1 |
| Lawrance, IC | 1 |
| Prosser, R | 1 |
| Bampton, P | 1 |
| Grafton, R | 1 |
| Simms, LA | 1 |
| Studd, C | 1 |
| Bell, SJ | 1 |
| Kennedy, MA | 1 |
| Halliwell, J | 1 |
| Gearry, RB | 4 |
| Radford-Smith, G | 1 |
| Andrews, JM | 2 |
| McHugh, PC | 1 |
| Sánchez Rodríguez, E | 1 |
| Ríos León, R | 1 |
| Mesonero Gismero, F | 1 |
| Albillos, A | 1 |
| Lopez-Sanroman, A | 1 |
| Takahashi, K | 1 |
| Bamba, S | 1 |
| Morita, Y | 1 |
| Nishida, A | 1 |
| Kawahara, M | 1 |
| Inatomi, O | 1 |
| Sugimoto, M | 1 |
| Sasaki, M | 1 |
| Andoh, A | 1 |
| Jharap, B | 3 |
| de Boer, NK | 4 |
| Stokkers, P | 1 |
| Hommes, DW | 1 |
| de Jong, DJ | 3 |
| van Elburg, RM | 1 |
| Nguyen, TV | 2 |
| Vu, DH | 1 |
| Nguyen, TM | 2 |
| Lachaux, A | 2 |
| Boulieu, R | 3 |
| Curkovic, I | 1 |
| Rentsch, KM | 2 |
| Frei, P | 1 |
| Fried, M | 2 |
| Rogler, G | 1 |
| Kullak-Ublick, GA | 2 |
| Jetter, A | 1 |
| Blaker, PA | 1 |
| Arenas-Hernandez, M | 1 |
| Smith, MA | 1 |
| Shobowale-Bakre, EA | 1 |
| Fairbanks, L | 1 |
| Irving, PM | 2 |
| Sanderson, JD | 1 |
| Marinaki, AM | 1 |
| Moon, W | 1 |
| Loftus, EV | 1 |
| Wong, DR | 1 |
| Coenen, MJ | 1 |
| Derijks, LJ | 2 |
| Vermeulen, SH | 1 |
| van Marrewijk, CJ | 1 |
| Klungel, OH | 1 |
| Scheffer, H | 1 |
| Franke, B | 1 |
| Guchelaar, HJ | 1 |
| Engels, LG | 2 |
| Verbeek, AL | 1 |
| Hooymans, PM | 2 |
| Stocco, G | 2 |
| Martelossi, S | 2 |
| Arrigo, S | 1 |
| Barabino, A | 1 |
| Aloi, M | 1 |
| Martinelli, M | 1 |
| Miele, E | 1 |
| Knafelz, D | 1 |
| Romano, C | 1 |
| Naviglio, S | 1 |
| Favretto, D | 1 |
| Cuzzoni, E | 1 |
| Franca, R | 1 |
| Decorti, G | 2 |
| Ventura, A | 2 |
| Alvarez Beltran, M | 1 |
| Infante Pina, D | 1 |
| Tormo Carnicé, R | 1 |
| Segarra Cantón, O | 1 |
| Redecillas Ferreiro, S | 1 |
| Joyce, JC | 1 |
| Wang, S | 1 |
| Saxena, A | 1 |
| Hart, M | 1 |
| Higgins, PD | 1 |
| de Graaf, P | 2 |
| Vos, RM | 1 |
| de Boer, NH | 1 |
| Sinjewel, A | 1 |
| Veldkamp, AI | 2 |
| Vikingsson, S | 1 |
| Carlsson, B | 1 |
| Almer, S | 1 |
| Peterson, C | 1 |
| Haines, ML | 1 |
| Ajlouni, Y | 1 |
| Sparrow, MP | 1 |
| Rose, R | 1 |
| Gibson, PR | 1 |
| Gerich, ME | 1 |
| Quiros, JA | 1 |
| Marcin, JP | 1 |
| Tennyson, L | 1 |
| Henthorn, M | 1 |
| Prindiville, TP | 1 |
| Londero, M | 1 |
| Campanozzi, A | 1 |
| Marino, S | 1 |
| Malusa, N | 1 |
| Bartoli, F | 1 |
| Pozler, O | 1 |
| Chládek, J | 1 |
| Malý, J | 1 |
| Hroch, M | 1 |
| Dědek, P | 1 |
| Beránek, M | 1 |
| Krásničanová, P | 1 |
| Roblin, X | 1 |
| Oussalah, A | 1 |
| Chevaux, JB | 1 |
| Sparrow, M | 1 |
| Peyrin-Biroulet, L | 1 |
| Armstrong, L | 1 |
| Sharif, JA | 1 |
| Galloway, P | 1 |
| McGrogan, P | 1 |
| Bishop, J | 1 |
| Russell, RK | 1 |
| Smid, K | 1 |
| van Asseldonk, DP | 2 |
| Bouma, G | 1 |
| Peters, GJ | 1 |
| van Egmond, R | 1 |
| Chin, P | 1 |
| Sies, CW | 1 |
| Shih, DQ | 1 |
| Nguyen, M | 1 |
| Zheng, L | 1 |
| Ibanez, P | 1 |
| Mei, L | 1 |
| Kwan, LY | 1 |
| Bradford, K | 1 |
| Ting, C | 1 |
| Targan, SR | 1 |
| Vasiliauskas, EA | 1 |
| Kennedy, NA | 1 |
| Asser, TL | 1 |
| Mountifield, RE | 1 |
| Doogue, MP | 1 |
| Bampton, PA | 1 |
| Bloomfeld, RS | 1 |
| Onken, JE | 1 |
| Gilissen, LP | 1 |
| Jansen, JB | 1 |
| Wright, S | 1 |
| Sanders, DS | 1 |
| Lobo, AJ | 1 |
| Lennard, L | 1 |
| Goldenberg, BA | 1 |
| Rawsthorne, P | 1 |
| Bernstein, CN | 1 |
| Hindorf, U | 1 |
| Lyrenäs, E | 1 |
| Nilsson, A | 1 |
| Wusk, B | 1 |
| Rammert, C | 1 |
| von Eckardstein, A | 1 |
| Dervieux, T | 1 |
| Meyer, G | 1 |
| Barham, R | 1 |
| Matsutani, M | 1 |
| Barry, M | 1 |
| Neri, B | 1 |
| Seidman, E | 1 |
| Banerjee, S | 1 |
| Bishop, WP | 1 |
| Gardiner, SJ | 1 |
| Begg, EJ | 1 |
| Sau, A | 1 |
| Marinaki, A | 1 |
| Swaminath, A | 1 |
| Kornbluth, A | 1 |
| Pike, MG | 1 |
| Franklin, CL | 1 |
| Mays, DC | 1 |
| Lipsky, JJ | 1 |
| Lowry, PW | 1 |
| Sandborn, WJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System.[NCT00521950] | 853 participants (Actual) | Interventional | 2007-09-30 | Completed | |||
| Manitoba Inflammatory Bowel Disease Cohort Study[NCT03262649] | 388 participants (Actual) | Observational | 2002-03-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for 6-methylthiopurine and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Addition of Allopurinol for Altering Thiopurine Metabolism to Optimize Therapy in Patients with Inflammatory Bowel Disease.
Topics: Allopurinol; Drug Therapy, Combination; Enzyme Inhibitors; Guanine Nucleotides; Humans; Immunosuppre | 2018 |
Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
Topics: Azathioprine; Humans; Inflammatory Bowel Diseases; Mercaptopurine; Methyltransferases; Pharmacogenet | 2016 |
Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
Topics: Antimetabolites, Antineoplastic; Azathioprine; Bone Marrow; Erythrocytes; Guanine Nucleotides; Human | 2005 |
Optimizing drug therapy in inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adalimumab; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal | 2007 |
6 trials available for 6-methylthiopurine and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Impact of Chronotherapy on 6-Mercaptopurine Metabolites in Inflammatory Bowel Disease: A Pilot Crossover Trial.
Topics: Azathioprine; Chronotherapy; Cross-Over Studies; Humans; Inflammatory Bowel Diseases; Mercaptopurine | 2023 |
Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease.
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Anemia, Neonatal; Azathioprine; Biomarkers; Female; | 2014 |
Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.
Topics: Adult; Aged; Allopurinol; Azathioprine; Female; Guanine Nucleotides; Humans; Inflammatory Bowel Dise | 2013 |
Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Chemical and Drug Induced Liver Injury; Cohort Studies | 2017 |
Allopurinol enhances the activity of hypoxanthine-guanine phosphoribosyltransferase in inflammatory bowel disease patients during low-dose thiopurine therapy: preliminary data of an ongoing series.
Topics: Adolescent; Adult; Allopurinol; Azathioprine; Child; Dose-Response Relationship, Drug; Drug Therapy, | 2011 |
6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
Topics: Adult; Azathioprine; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug | 2003 |
36 other studies available for 6-methylthiopurine and Bowel Diseases, Inflammatory
| Article | Year |
|---|---|
Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life.
Topics: Adalimumab; Adult; Anti-Bacterial Agents; Autoimmune Diseases; Cesarean Section; Child Development; | 2021 |
Machine Learning Algorithms for Objective Remission and Clinical Outcomes with Thiopurines.
Topics: Adolescent; Adult; Algorithms; Area Under Curve; Azathioprine; Drug Prescriptions; Female; Hospitali | 2017 |
A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease.
Topics: Adult; Antibodies; Drug Synergism; Drug Therapy, Combination; Erythrocytes; Female; Gastrointestinal | 2018 |
Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine.
Topics: Adult; Aged; Aged, 80 and over; Azathioprine; Female; Humans; Inflammatory Bowel Diseases; Male; Mer | 2018 |
Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.
Topics: Adolescent; Adult; Allopurinol; Azathioprine; Child; Child, Preschool; Dose-Response Relationship, D | 2018 |
Nonsynonymous Polymorphism in Guanine Monophosphate Synthetase Is a Risk Factor for Unfavorable Thiopurine Metabolite Ratios in Patients With Inflammatory Bowel Disease.
Topics: Adult; Azathioprine; Carbon-Nitrogen Ligases with Glutamine as Amide-N-Donor; Cohort Studies; Female | 2018 |
Clinical experience of optimising thiopurine use through metabolite measurement in inflammatory bowel disease.
Topics: Adult; Aged; Azathioprine; Biotransformation; Dose-Response Relationship, Drug; Drug Monitoring; Fem | 2018 |
pH-Dependent 5-Aminosalicylates Releasing Preparations Do Not Affect Thiopurine Metabolism.
Topics: Administration, Oral; Adolescent; Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; | 2019 |
Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis.
Topics: Adolescent; Age Factors; Azathioprine; Child; Dose-Response Relationship, Drug; Female; Guanine Nucl | 2013 |
Mechanism of allopurinol induced TPMT inhibition.
Topics: Adult; Allopurinol; Azathioprine; Case-Control Studies; Drug Therapy, Combination; Erythrocytes; Fem | 2013 |
Usefulness of thiopurine metabolites in predicting azathioprine resistance in pediatric IBD patients.
Topics: Adolescent; Antimetabolites; Azathioprine; Child; Child, Preschool; Drug Resistance; Female; Humans; | 2013 |
Multicentric Case-Control Study on Azathioprine Dose and Pharmacokinetics in Early-onset Pediatric Inflammatory Bowel Disease.
Topics: Adolescent; Age of Onset; Antimetabolites; Azathioprine; Case-Control Studies; Child; Child, Prescho | 2017 |
[Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites].
Topics: Adolescent; Azathioprine; Female; Hepatitis, Autoimmune; Humans; Immunosuppressive Agents; Inflammat | 2009 |
Algorithms outperform metabolite tests in predicting response of patients with inflammatory bowel disease to thiopurines.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Artificial Intelligence; Child; Child, Presc | 2010 |
Limited stability of thiopurine metabolites in blood samples: relevant in research and clinical practise.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Inflammatory Bowel Diseases; Mercaptop | 2010 |
How should thiopurine treatment be monitored?--methodological aspects.
Topics: Humans; Immunosuppressive Agents; Inflammatory Bowel Diseases; Mercaptopurine; Purines; Thioguanine | 2010 |
Clinical usefulness of therapeutic drug monitoring of thiopurines in patients with inadequately controlled inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Azathioprine; Chromatography, High Pressure Liquid; Colitis, Ulcerative; Cr | 2011 |
A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Allopurinol; Child; Child, Preschool; Drug Administratio | 2010 |
Usefulness of the measurement of azathioprine metabolites in the assessment of non-adherence.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Female; Guanine Nucleotides; Hepatitis, Autoimmun | 2010 |
Steady-state of azathioprine during initiation treatment of pediatric inflammatory bowel disease.
Topics: Adolescent; Azathioprine; Child; Child, Preschool; Female; Genotype; Guanine Nucleotides; Humans; Im | 2010 |
Use of thiopurine testing in the management of inflammatory bowel diseases in clinical practice: a worldwide survey of experts.
Topics: Azathioprine; Biomarkers; Cross-Sectional Studies; Gastroenterology; Genetic Testing; Genotype; Glob | 2011 |
Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
Topics: Adolescent; Azathioprine; Biomarkers; Chromatography, High Pressure Liquid; Dose-Response Relationsh | 2011 |
Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
Topics: Antimetabolites, Antineoplastic; Azathioprine; Chemical and Drug Induced Liver Injury; Female; Human | 2012 |
High TPMT enzyme activity does not explain drug resistance due to preferential 6-methylmercaptopurine production in patients on thiopurine treatment.
Topics: Antimetabolites, Antineoplastic; Azathioprine; Chromatography, High Pressure Liquid; Drug Resistance | 2012 |
Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism.
Topics: Adolescent; Adult; Azathioprine; Dose-Response Relationship, Drug; Erythrocytes; Female; Humans; Imm | 2012 |
Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease.
Topics: Adult; Biomarkers; Disease Management; Female; Guanine Nucleotides; Humans; Inflammatory Bowel Disea | 2013 |
Mercaptopurine metabolite results in clinical gastroenterology practice.
Topics: Azathioprine; Humans; Inflammatory Bowel Diseases; Mercaptopurine; Patient Compliance; Risk Factors; | 2003 |
Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antimetabolites, Antineoplastic; Azathioprine; Child; | 2004 |
The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease.
Topics: Adult; Azathioprine; Biomarkers; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Dose-Response R | 2004 |
Monitoring of long-term thiopurine therapy among adults with inflammatory bowel disease.
Topics: Adolescent; Adult; Azathioprine; Drug Monitoring; Erythrocytes; Female; Genotype; Guanine Nucleotide | 2004 |
Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cohort Studi | 2004 |
Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
Topics: Adult; Azathioprine; Chromatography, Liquid; Cohort Studies; Drug Therapy, Combination; Erythrocytes | 2005 |
Evolution of thiopurine use in pediatric inflammatory bowel disease in an academic center.
Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Erythr | 2006 |
Thiopurine treatment in inflammatory bowel disease.
Topics: Adult; Antimetabolites; Breast Feeding; Dose-Response Relationship, Drug; Female; Humans; Infant; In | 2007 |
Stability of thiopurine metabolites: a potential analytical bias.
Topics: Bias; Guanine Nucleotides; Humans; Inflammatory Bowel Diseases; Mercaptopurine; Prospective Studies; | 2008 |
Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood.
Topics: Chromatography, High Pressure Liquid; Humans; Inflammatory Bowel Diseases; Mercaptopurine; Reproduci | 2001 |